Teva Pharmaceutical Industries Ltd. posted a fourth-quarter net profit of $680 million, a 28% increase from the prior year and exceeding consensus estimates by $50 million. Revenue climbed 10% to $4.9 billion, driven by a 22% jump in branded specialty sales, which reached $1.8 billion. The company recognized a $75 million milestone payment upon initiation of a Phase III trial for its investigational ulcerative colitis and Crohn’s disease candidate. Excluding one-time items, adjusted earnings per share came in at $0.68, topping analyst forecasts of $0.62. Teva’s cost of goods sold ratio improved by 150 basis points to 46.3%, reflecting manufacturing efficiencies in its generics division, while R&D spending rose 14% to $650 million as the firm advanced strategic programs in neuroscience and immunology.

Teva Pharmaceuticals’ U.S. affiliate has appointed actor and advocate Will Forte as ambassador for its ‘Honestly HD’ program to raise public and professional awareness of Huntington’s disease (HD). The campaign highlights that more than 41,000 Americans live with HD and that chorea, an involuntary movement disorder, affects up to 90% of patients. Forte’s involvement follows his brother-in-law’s 2022 diagnosis and will leverage personal storytelling and digital outreach to connect patients and caregivers with Teva’s educational resources. Teva will allocate $3 million in 2026 to expand online HD chorea support tools and plans to host regional patient-caregiver workshops in five major U.S. cities. Heather DeMyers, Vice President of U.S. Innovative Medicines Marketing, noted that the program underscores Teva’s commitment to neurological disorders after investing over $200 million in HD research since 2020.